- Home
- ICU vs KZIA Comparison
ICU vs KZIA Comparison
Compare ICU & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- KZIA
- Stock Information
- Founded
- ICU 2018
- KZIA 1994
- Country
- ICU United States
- KZIA Australia
- Employees
- ICU N/A
- KZIA N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- KZIA Health Care
- Exchange
- ICU Nasdaq
- KZIA Nasdaq
- Market Cap
- ICU 8.9M
- KZIA 7.8M
- IPO Year
- ICU N/A
- KZIA 1999
- Fundamental
- Price
- ICU $1.75
- KZIA $1.42
- Analyst Decision
- ICU
- KZIA Strong Buy
- Analyst Count
- ICU 0
- KZIA 1
- Target Price
- ICU N/A
- KZIA $20.00
- AVG Volume (30 Days)
- ICU 24.8K
- KZIA 116.4K
- Earning Date
- ICU 11-13-2024
- KZIA 11-15-2024
- Dividend Yield
- ICU N/A
- KZIA N/A
- EPS Growth
- ICU N/A
- KZIA N/A
- EPS
- ICU N/A
- KZIA N/A
- Revenue
- ICU $68,000.00
- KZIA $1,655,324.00
- Revenue This Year
- ICU N/A
- KZIA $806.89
- Revenue Next Year
- ICU $358.72
- KZIA N/A
- P/E Ratio
- ICU N/A
- KZIA N/A
- Revenue Growth
- ICU N/A
- KZIA 248000.00
- 52 Week Low
- ICU $1.68
- KZIA $1.39
- 52 Week High
- ICU $42.93
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- ICU 34.18
- KZIA 20.74
- Support Level
- ICU $1.68
- KZIA $1.42
- Resistance Level
- ICU $2.01
- KZIA $1.89
- Average True Range (ATR)
- ICU 0.13
- KZIA 0.24
- MACD
- ICU -0.01
- KZIA 0.02
- Stochastic Oscillator
- ICU 14.00
- KZIA 1.40
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.